BioSpace News Archive

Prodol Meditec, SA, manufacturer of the Airtraq video laryngoscope and camera system, has selected Mercury Medical as their Exclusive North America Distributor partner for their state-of-the-art video laryngoscope product line effective January 1, 2022.

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Merck’s Keytruda (pembrolizumab) to include patients with Stage IIB and IIC melanoma.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2021.

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company’s compound, GZR18, to improve the management of type 2 diabetes mellitus.

Inventiva announced the results of a clinical thorough QT/QTc study1 demonstrating the safety of lanifibranor on cardiac electrical activity.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021.

Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA ® Blood Test Since Its Launch A Year Ago.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), today announced that several abstracts relating to the Secura Bio product COPIKTRA® (duvelisib) will be presented at the 63rd annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today announced that it has completed patient enrollment in its Pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

Yarrow Biotechnology, Inc., an RTW-incubated company developing antisense oligonucleotide (ASO) therapeutics for severe, genetically defined CNS diseases, today announced the appointment of Dr. Mark T. Keating as Chief Scientific Officer.